|
|
| |
| |
|
| |
Matossian Eye provides Continued Education for Medical Residents |
| |
Cynthia Matossian, MD, Ilya Rozenbaum, MD and Priya Desai, MD each presented a lecture to
read full article |
| |
|
| |
U.S. News and the Star Ledger Names Local Ophthalmologist “Top Doctor” |
| |
|
| |
|
| |
Thursday, February 23, 2012 |
| |
05:30 PM To 06:30 PM |
| |
Cynthia Matossian, MD was invited to speak to aspiring doctors on how she successfully balanced her view event
|
| |
|
| |
Thursday, March 01, 2012 |
| |
06:30 PM To 07:30 PM |
| |
Cynthia Matossian, MD will be discussing Pataday and its benefits with use for allergies with New Br view event
|
| |
|
| |
Thursday, March 08, 2012 |
| |
06:30 PM To 07:25 PM |
| |
Cynthia Matossian, MD will be discussing Pataday and its benefits with use for allergies with Prince view event
|
| |
|
|
|
|
| |
|
|
 |
 |
| |
|
|
|
A clinical trial is a medical research study conducted to evaluate and answer specific questions about a potential treatment for use in patient care. Researchers conduct clinical trials to determine the safety and efficacy of new drugs or study the use of established drugs in new ways.
Clinical trials are meant to benefit future patients. They are performed to assess the potential value of a new therapy without offering proven results.
Clinical trials are never performed until careful scientific research has been conducted to indicate a potential benefit.
Participation in clinical trials is voluntary. Patients can discontinue participation at any time and it will not affect their relationship with their doctor(s) or employees involved in the study.
At MEA we stay current with the latest technology and are honored to be asked to participate in many clinical trials.
| 2004 |
Wills Eye Hospital – Internet Based Study, Is One of Two Topical Prostaglandin Analogues Significantly More Tolerable Than the Other: Bimatroprost v. Latanoprost? |
| 2005 – 06 |
Alcon Pharmaceutical, Travatan dosing aid study |
| 2007 |
Allergan, Inc. – Phase IV – A Multicenter, Masked Evaluation of Ocular Surface Tolerability Associated with Bimatoprost 0.03%, Travoprost 0.004% (BAK free) or Latanoprost 0.005% Therapy in Patients with Glaucoma or Ocular Hypertension. |
| 2008 |
Ista Pharmaceuticals – Phase II – A Multi-Center, Double Blind, Vehicle-Controlled, Randomized Study of Ecabet Ophthalmic Solution in Patients with Dry Eye Disease |
| 2008 |
Allergan, Inc. – Phase IV – A Multi-Center, investigator-masked, randomzed, parallel study to compare the IOP lowering efficacy and safety of Combigan (fixed combination of 0.2% Brimonidine Tartrte and 0.5% Timolol Maleate) with Timolol (0.5% Timolol Maleate), when each is used as adjunctive therapy to Xalatan (0.005% Latanoprost) in subjects with Open-Angle Glaucoma and Ocular Hypertension. |
| 2009 |
Sanofi-Aventis – Providing ophthalmologic evaluations for a study in which Tamaris, a vascular endothelial growth factor, is being used to help peripheral blood vessels. The study requires dilated ophthalmic funduscopic exams to participants on scheduled intervals |
| 2009 |
Ista Pharmaceuticals – Efficacy and Safety of Bromfenac Ophthalmic Solution QD vs. Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery |
| 2010 |
Abbot Medical Optics – Evaluation of Blink® artificial tears on its effectiveness for the symptoms of dry eye syndrome |
| 2010 |
Ista Pharmaceuticals – 6 Month Dry Eye Study |
|
| |
| |
|
|
| |
| |
|
Home  About Us Services  Cataract Surgery Glaucoma Contact Lenses Products Testimonials |
| News Event Recommended Links Privacy Notice/Forms Educational Videos Eye Problems Contact Us |
| |
|
